<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439072</url>
  </required_header>
  <id_info>
    <org_study_id>XSGP-303</org_study_id>
    <nct_id>NCT03439072</nct_id>
  </id_info>
  <brief_title>G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes</brief_title>
  <official_title>G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adults With T1D: a Phase 3 B Multi-Centered, Randomized, Controlled, Single Blind, 2-Way Crossover Study to Evaluate Efficacy and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SGS S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Integrated Medical Development</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-inferiority, multi-center, randomized, controlled, single-blind, two-way
      crossover efficacy and safety study in subjects with Type 1 diabetes mellitus. The study
      involves two daytime clinical research center (CRC) visits with random assignment to receive
      G-Pen™ glucagon 1 mg during one period and Lilly Glucagon 1 mg during the other. Each daytime
      visit is preceded by an overnight stay in the CRC. In the morning of the inpatient study
      visit, the subject is brought into a state of hypoglycemia through IV administration of
      regular insulin diluted in normal saline. After a hypoglycemic state with plasma glucose &lt; 50
      mg/dL is verified, the subject is administered a dose of G-Pen or Lilly Glucagon via
      subcutaneous injection. Plasma glucose levels are monitored for up to 180 minutes
      post-dosing, with a value of &gt;70.0 mg/dL within 30 minutes of glucagon administration
      indicating a positive response. After 3 hours, the subject is given a meal and discharged
      when medically stable. After a wash-out period of 7 to 28 days, subjects return to the CRC,
      and the procedure are repeated with each subject crossed over to the other treatment. A
      follow-up visit as a safety check is conducted 2-7 days following administration of the final
      dose of study drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 23, 2018</start_date>
  <completion_date type="Actual">May 3, 2018</completion_date>
  <primary_completion_date type="Actual">April 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With a Positive Glucose Response</measure>
    <time_frame>0 to 30 minutes post dose</time_frame>
    <description>Increase in plasma glucose concentration from below 50.0 mg/dL to greater than 70.0 mg/dL within 30 minutes after receiving glucagon</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for Positive Glucose Response</measure>
    <time_frame>0 to 180 minutes post dose</time_frame>
    <description>Time from administration of glucagon for plasma glucose to rise from below 50.0 mg/dL to above 70.0 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Positive Glucose Increase</measure>
    <time_frame>0 to 30 minutes post dose</time_frame>
    <description>A positive response for this endpoint is a return of plasma glucose to &gt; 70 mg/dL or an increase in plasma glucose by ≥20 mg/dL within 30 minutes after receiving glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Positive Glucose Increase</measure>
    <time_frame>0 to 30 minutes post dose</time_frame>
    <description>Increase in plasma glucose by ≥ 20.0 mg/dL within 30 minutes after receiving glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for Positive Glucose Increase</measure>
    <time_frame>0 to 180 minutes post dose</time_frame>
    <description>Time from administration of glucagon for plasma glucose to increase by ≥20 mg/dL from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Relief of Neuroglycopenic Symptoms</measure>
    <time_frame>0 to 30 minutes post dose</time_frame>
    <description>A positive response for this endpoint is a return of plasma glucose to &gt; 70 mg/dL or clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Relief of Neuroglycopenic Symptoms</measure>
    <time_frame>0 to 30 minutes post dose</time_frame>
    <description>Clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Autonomic Symptoms</measure>
    <time_frame>0 to 180 minutes post dose</time_frame>
    <description>Time from administration of glucagon to complete resolution of 4 autonomic symptoms of hypoglycemia. Symptoms included: sweating, tremor, palpitations and feeling of nervousness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Neuroglycopenic Symptoms</measure>
    <time_frame>0 to 180 minutes post dose</time_frame>
    <description>Time from administration of glucagon to complete resolution of 4 neuroglycopenic symptoms of hypoglycemia. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of the Feeling of Hypoglycemia</measure>
    <time_frame>0 to 180 minutes post dose</time_frame>
    <description>Time from administration of glucagon to resolution of the overall sensation of hypoglycemia. Subjects were asked to answer yes/no to the question, &quot;Do you feel hypoglycemic?&quot; The time point as which the subject first answered &quot;no&quot; was considered the time of resolution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose AUC</measure>
    <time_frame>0 to 180 minutes post dose - Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.</time_frame>
    <description>Area under the curve for plasma glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Cmax</measure>
    <time_frame>0 to 180 minutes post dose - Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.</time_frame>
    <description>Maximum concentration of plasma glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Tmax</measure>
    <time_frame>0 to 180 minutes post dose</time_frame>
    <description>Time to maximum concentration of plasma glucose. Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon Preparation and Administration Time</measure>
    <time_frame>0 to 5 minutes pre-dose</time_frame>
    <description>Time required to prepare and inject glucagon as measured between a &quot;decision to dose&quot; and completion of the injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Insulin Hypoglycemia</condition>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Severe Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>G-Pen followed by Lilly Glucagon</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lilly Glucagon followed by G-Pen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-Pen</intervention_name>
    <description>1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
    <arm_group_label>G-Pen followed by Lilly Glucagon</arm_group_label>
    <arm_group_label>Lilly Glucagon followed by G-Pen</arm_group_label>
    <other_name>glucagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lilly Glucagon</intervention_name>
    <description>1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
    <arm_group_label>G-Pen followed by Lilly Glucagon</arm_group_label>
    <arm_group_label>Lilly Glucagon followed by G-Pen</arm_group_label>
    <other_name>GEK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females diagnosed with type 1 diabetes mellitus for at least 24 months.

          2. Current usage of daily insulin treatment that includes having an assigned &quot;correction
             factor&quot; for managing hyperglycemia.

          3. Age 18-75 years, inclusive.

          4. Random serum C-peptide concentration &lt; 0.5 ng/mL.

          5. Willingness to follow all study procedures, including attending all clinic visits.

          6. Subject has provided informed consent as evidenced by a signed/dated informed consent
             form completed before any trial-related activities occur.

        Exclusion Criteria:

          1. Pregnancy: For women of childbearing potential, there is a requirement for a negative
             urine pregnancy test and for agreement to use contraception throughout the study and
             for 7 days after the last dose of study glucagon. Acceptable contraception includes
             birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double
             barrier method (the woman uses a diaphragm and spermicide and the man uses a condom),
             or abstinence.

          2. Breastfeeding: Nursing mothers will be allowed into the study. However, breast feeding
             during the during inpatient study visits and for 48 hours after each dose of study
             drug is not allowed.

          3. HbA1c &gt;9.0% at Screening.

          4. BMI &gt; 40 kg/m2.

          5. Renal insufficiency (serum creatinine greater than 3.0 mg/dL) or end-stage renal
             disease. requiring renal replacement therapy.

          6. Serum ALT or AST equal to or greater than 3 times the upper limit of normal.

          7. Hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL.

          8. Hematocrit of less than or equal to 30%.

          9. BP readings at Screening where SBP &lt;90 or &gt;150 mm Hg, and DBP &lt;50 or &gt;100 mm Hg.

         10. Clinically significant ECG abnormalities.

         11. Use of &gt; 2.0 U/kg total insulin dose per day.

         12. Inadequate venous access.

         13. Congestive heart failure, NYHA class III or IV.

         14. History of myocardial infarction, unstable angina, or revascularization within the
             past 6 months.

         15. History of a cerebrovascular accident in past 6 months or with major neurological
             deficits.

         16. Active malignancy within 5 years from Screening, except basal cell or squamous cell
             skin cancers. History of breast cancer or malignant melanoma will be exclusionary.

         17. Major surgical operation within 30 days prior to Screening.

         18. Current seizure disorder (other than with suspect or documented hypoglycemia).

         19. Current bleeding disorder, treatment with warfarin, or platelet count below 50 x 10e9
             per liter.

         20. History of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN
             2, neurofibromatosis, or Von Hippel-Lindau disease).

         21. History of insulinoma.

         22. History of allergies to glucagon or glucagon-like products, or any history of
             significant hypersensitivity to glucagon or any related products or to any of the
             excipients (DMSO &amp; trehalose) in the investigational formulation.

         23. History of glycogen storage disease.

         24. Subject tests positive for HIV, HCV or HBV infection (HBsAg+) at Screening.

         25. Active substance or alcohol abuse (more than 21 drinks/wk. for males or 14 drinks/wk.
             for females). Subjects reporting active marijuana use or testing positive for
             tetrahydrocannabinol (THC) via rapid urine test will be allowed to participate in the
             study at the discretion of the Investigator.

         26. Administration of glucagon within 28 days of Screening.

         27. Participation in other studies involving administration of an investigational drug or
             device within 30 days or 5 half-lives, whichever is longer, before Screening for the
             current study and during participation in the current study.

         28. Any reason the Investigator deems exclusionary.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ProSciento, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center, Inc.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMC ESD, Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altasciences Algorithme Pharma</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <results_first_submitted>April 17, 2019</results_first_submitted>
  <results_first_submitted_qc>May 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2019</results_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucagon</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03439072/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03439072/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period began 08 Jan 2018 and ran through 02 Apr 2018. Subjects were screened for study eligibility at one of the six clinical sites up to 30 days prior to randomization.</recruitment_details>
      <pre_assignment_details>A total of 81 eligible subjects were randomized to treatment. However, two subjects withdrew consent prior to dosing, so the number of subjects exposed to study treatment was 79.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>G-Pen Followed by Lilly Glucagon</title>
          <description>1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit
G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
        </group>
        <group group_id="P2">
          <title>Lilly Glucagon Followed by G-Pen</title>
          <description>1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39">1 subject dropped before G-Pen; another after G-Pen (n=40 G-Pen; N=39 Lilly Glucagon)</participants>
                <participants group_id="P2" count="36">1 subject dropped before Lilly Glucagon; 3 others after Lilly Glucagon (N=39 Lilly; N=36 G-Pen)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>All Randomized Subjects</title>
          <description>A total of 81 subjects met eligibility requirements and were randomized to study treatment.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a Positive Glucose Response</title>
        <description>Increase in plasma glucose concentration from below 50.0 mg/dL to greater than 70.0 mg/dL within 30 minutes after receiving glucagon</description>
        <time_frame>0 to 30 minutes post dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Positive Glucose Response</title>
          <description>Increase in plasma glucose concentration from below 50.0 mg/dL to greater than 70.0 mg/dL within 30 minutes after receiving glucagon</description>
          <population>Intent to treat analysis population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time for Positive Glucose Response</title>
        <description>Time from administration of glucagon for plasma glucose to rise from below 50.0 mg/dL to above 70.0 mg/dL</description>
        <time_frame>0 to 180 minutes post dose</time_frame>
        <population>Intent-to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Positive Glucose Response</title>
          <description>Time from administration of glucagon for plasma glucose to rise from below 50.0 mg/dL to above 70.0 mg/dL</description>
          <population>Intent-to treat analysis population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.17" spread="3.604"/>
                    <measurement group_id="O2" value="8.58" spread="2.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Positive Glucose Increase</title>
        <description>A positive response for this endpoint is a return of plasma glucose to &gt; 70 mg/dL or an increase in plasma glucose by ≥20 mg/dL within 30 minutes after receiving glucagon</description>
        <time_frame>0 to 30 minutes post dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Positive Glucose Increase</title>
          <description>A positive response for this endpoint is a return of plasma glucose to &gt; 70 mg/dL or an increase in plasma glucose by ≥20 mg/dL within 30 minutes after receiving glucagon</description>
          <population>Intent to treat analysis population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Positive Glucose Increase</title>
        <description>Increase in plasma glucose by ≥ 20.0 mg/dL within 30 minutes after receiving glucagon</description>
        <time_frame>0 to 30 minutes post dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Positive Glucose Increase</title>
          <description>Increase in plasma glucose by ≥ 20.0 mg/dL within 30 minutes after receiving glucagon</description>
          <population>Intent to treat analysis population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time for Positive Glucose Increase</title>
        <description>Time from administration of glucagon for plasma glucose to increase by ≥20 mg/dL from baseline</description>
        <time_frame>0 to 180 minutes post dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Time for Positive Glucose Increase</title>
          <description>Time from administration of glucagon for plasma glucose to increase by ≥20 mg/dL from baseline</description>
          <population>Intent to treat analysis population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.36" spread="3.345"/>
                    <measurement group_id="O2" value="8.02" spread="1.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Relief of Neuroglycopenic Symptoms</title>
        <description>A positive response for this endpoint is a return of plasma glucose to &gt; 70 mg/dL or clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.</description>
        <time_frame>0 to 30 minutes post dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Positive Response for the Combination Endpoint: Positive Glucose Response/Relief of Neuroglycopenic Symptoms</title>
          <description>A positive response for this endpoint is a return of plasma glucose to &gt; 70 mg/dL or clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.</description>
          <population>Intent to treat analysis population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Relief of Neuroglycopenic Symptoms</title>
        <description>Clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.</description>
        <time_frame>0 to 30 minutes post dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Relief of Neuroglycopenic Symptoms</title>
          <description>Clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.</description>
          <population>Intent to treat analysis population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Autonomic Symptoms</title>
        <description>Time from administration of glucagon to complete resolution of 4 autonomic symptoms of hypoglycemia. Symptoms included: sweating, tremor, palpitations and feeling of nervousness.</description>
        <time_frame>0 to 180 minutes post dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Autonomic Symptoms</title>
          <description>Time from administration of glucagon to complete resolution of 4 autonomic symptoms of hypoglycemia. Symptoms included: sweating, tremor, palpitations and feeling of nervousness.</description>
          <population>Intent to treat analysis population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="10.89"/>
                    <measurement group_id="O2" value="12.0" spread="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Neuroglycopenic Symptoms</title>
        <description>Time from administration of glucagon to complete resolution of 4 neuroglycopenic symptoms of hypoglycemia. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.</description>
        <time_frame>0 to 180 minutes post dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Neuroglycopenic Symptoms</title>
          <description>Time from administration of glucagon to complete resolution of 4 neuroglycopenic symptoms of hypoglycemia. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.</description>
          <population>Intent to treat analysis population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="15.12"/>
                    <measurement group_id="O2" value="12.2" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of the Feeling of Hypoglycemia</title>
        <description>Time from administration of glucagon to resolution of the overall sensation of hypoglycemia. Subjects were asked to answer yes/no to the question, &quot;Do you feel hypoglycemic?&quot; The time point as which the subject first answered &quot;no&quot; was considered the time of resolution.</description>
        <time_frame>0 to 180 minutes post dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of the Feeling of Hypoglycemia</title>
          <description>Time from administration of glucagon to resolution of the overall sensation of hypoglycemia. Subjects were asked to answer yes/no to the question, &quot;Do you feel hypoglycemic?&quot; The time point as which the subject first answered &quot;no&quot; was considered the time of resolution.</description>
          <population>Intent to treat analysis population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="6.45"/>
                    <measurement group_id="O2" value="13.1" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose AUC</title>
        <description>Area under the curve for plasma glucose.</description>
        <time_frame>0 to 180 minutes post dose - Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.</time_frame>
        <population>Intent to treat analysis population. Due to missing data AUC was only evaluable in 67 subjects per arm.</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose AUC</title>
          <description>Area under the curve for plasma glucose.</description>
          <population>Intent to treat analysis population. Due to missing data AUC was only evaluable in 67 subjects per arm.</population>
          <units>mg∙min/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33686.04" spread="5300.204"/>
                    <measurement group_id="O2" value="33538.60" spread="5705.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Cmax</title>
        <description>Maximum concentration of plasma glucose.</description>
        <time_frame>0 to 180 minutes post dose - Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Cmax</title>
          <description>Maximum concentration of plasma glucose.</description>
          <population>Intent to treat analysis population</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.32" spread="45.626"/>
                    <measurement group_id="O2" value="228.11" spread="46.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose Tmax</title>
        <description>Time to maximum concentration of plasma glucose. Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.</description>
        <time_frame>0 to 180 minutes post dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tmax</title>
          <description>Time to maximum concentration of plasma glucose. Blood samples for assessment of blood glucose concentration were collected every 5 minutes post-dose to 90 minutes, and then at 120, 150 and 180 minutes post dose.</description>
          <population>Intent to treat analysis population</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.67" spread="33.513"/>
                    <measurement group_id="O2" value="113.89" spread="31.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucagon Preparation and Administration Time</title>
        <description>Time required to prepare and inject glucagon as measured between a &quot;decision to dose&quot; and completion of the injection</description>
        <time_frame>0 to 5 minutes pre-dose</time_frame>
        <population>Intent to treat analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>G-Pen</title>
            <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])</description>
          </group>
        </group_list>
        <measure>
          <title>Glucagon Preparation and Administration Time</title>
          <description>Time required to prepare and inject glucagon as measured between a &quot;decision to dose&quot; and completion of the injection</description>
          <population>Intent to treat analysis population</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="19.66"/>
                    <measurement group_id="O2" value="97.2" spread="45.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for up to 9 weeks, from the time of consent through the follow-up visit.</time_frame>
      <desc>Treatment-Emergent Adverse Events
Note: Some subjects experienced multiple adverse events. Consequently, the sum of the number of subjects experiencing each individual adverse events is greater than the number of unique subjects experiencing at least one adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>G-Pen</title>
          <description>G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector. Between the 2 arms, a total of 76 subjects received a dose of G-Pen in the study.</description>
        </group>
        <group group_id="E2">
          <title>Lilly Glucagon</title>
          <description>Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin]). Between the 2 arms, a total of 78 subjects received a dose of Lilly Glucagon in the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Neither the Institution nor the principal investigator may submit for publication or presentation, the results of this trial without prior written consent of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin J. Cummins</name_or_title>
      <organization>Xeris Pharmaceuticals, Inc.</organization>
      <phone>312-736-1624</phone>
      <email>mcummins@xerispharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

